Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4174MR)

This product GTTS-WQ4174MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4174MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13948MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ655MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ14850MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ13574MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ11103MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ5556MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP-771
GTTS-WQ8454MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ11211MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-1873
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW